Lymphoma and CLL at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
81 organizations at ASH 2026 present work in lymphoma & CLL: 34 hospitals and cancer centres, 18 pharma and biotech companies, 16 universities and research institutes, 7 suppliers and service providers and 6 government and non-profit bodies. Between them they bring 76 presentations to the program. Most represented: Memorial Sloan Kettering Cancer Center (18 on the program), Dana-Farber Cancer Institute (18 on the program), MD Anderson Cancer Center (16 on the program). 56 of them have their own page in this guide. As of Sep 27, 2026.
Format
Top represented
Showing 1–2 of 81 organizations
| Organization | ASH 2026 Attendance |
|---|---|
Memorial Sloan Kettering Cancer Center New York, NY | |
NCI-designated comprehensive cancer center in New York City combining cancer care, research and education. | Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 11:00am–2:00pm CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life First-line drug choice, resistance, long-term side effects, and treatment-free remission in chronic myeloid leukemia, plus pipeline agents. Symposium Fri Dec 11 3:00pm–6:00pm Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care Sequencing CAR-T and T-cell engagers for relapsed myeloma, when to refer, managing toxicity, and options after B-cell maturation antigen therapy fails. Symposium Fri Dec 11 3:00pm–6:00pm Live Tumor Board: Advancing Clinical Competence in Primary CNS Lymphoma — Navigating Molecular Pathways and Emerging Therapies Treating primary central nervous system lymphoma, from methotrexate-based induction and consolidation choices to new drugs aimed at its signaling mutations. Symposium Fri Dec 11 11:00am–2:00pm Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs. Session Designing Microbiome-Directed Interventional Trials in Hematologic Malignancies How to design clinical trials that alter the gut microbiome in blood cancers, including fecal microbiota transplants to prevent graft-versus-host disease. Talk Dietary and Prebiotic Intervention Strategies Changing gut bacteria through diet and prebiotic fiber, the evidence linking food to patient outcomes, and how to design rigorous nutrition trials. Talk Live Bacterial Therapeutic Intervention Strategies Giving patients defined mixtures of live bacteria to reshape the gut and cut infections after a donor stem cell transplant. Talk Novel Uses of RNA as Therapeutics Synthetic RNAs that exploit faulty splicing to kill cancer cells with splicing-factor mutations, and mRNA vaccines against mis-spliced protein fragments. Session Advancing Personalized Care in Classic Hodgkin Lymphoma Tailoring classic Hodgkin lymphoma treatment to risk, response and circulating tumor DNA to cure with less toxicity, plus personalized follow-up care. Talk Bispecific Antibodies and Cellular Therapies for Diffuse Large B-Cell Lymphoma CAR-T cells and bispecific antibodies for diffuse large B-cell lymphoma, covering efficacy, side effects, patient selection, sequencing, and drugs in development. Talk Immune Determinants of Infections after CAR T- Cell Therapy: A Framework for Prevention and Management Infection risk after CAR-T cell therapy, traced from early immune damage to lasting antibody deficits, and how to prevent infections at each stage. Talk Acute Lymphoblastic Leukemia in Adolescents and Young Adults: Improving Outcomes Beyond the Use of Two Pediatric Regimens Raising cure rates for teens and young adults with acute lymphoblastic leukemia by adding immunotherapy to pediatric-style regimens and limiting lasting harm. Session From Real-World Evidence to Real-World Impact: Translating Multiple Myeloma Data into Clinical Practice Case studies showing how real-world multiple myeloma data reveal treatment patterns, outcomes in underrepresented groups, and care gaps, along with their limits. Session The AI Colleague: Promise, Peril, and Practice in Hematology Generative AI in hematology, from chatbot tools usable today to autonomous agents, and safeguards for reliability, bias, and human oversight. |
Dana-Farber Cancer Institute Boston, MA | |
Harvard-affiliated cancer treatment and research center in Boston, Massachusetts. | Symposium Fri Dec 11 11:00am–2:00pm Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum Bispecific antibodies in relapsed diffuse large B-cell and follicular lymphoma, from sequencing with CAR-T to outpatient step-up dosing and side effects. Symposium Fri Dec 11 11:00am–2:00pm Cases and Conversations™: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies Diagnosing blastic plasmacytoid dendritic cell neoplasm and treating it with drugs aimed at the interleukin-3 receptor, while managing capillary leak syndrome. Symposium Fri Dec 11 11:00am–2:00pm Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making Using tests for isocitrate dehydrogenase and Flt3 mutations to guide targeted therapy choices in acute myeloid leukemia. Symposium Fri Dec 11 3:00pm–6:00pm FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk. Symposium Fri Dec 11 7:00am–10:00am MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum Managing myelodysplastic neoplasms across their spectrum, from clonal hematopoiesis and lower- and higher-risk disease to overlap syndromes and leukemia. Symposium Fri Dec 11 7:00pm–10:00pm Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia Pediatric-style regimens, asparaginase, immunotherapy, and CAR-T for teens and young adults with acute lymphoblastic leukemia, plus their psychosocial needs. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. Symposium Fri Dec 11 11:00am–2:00pm The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care Cereblon-modulating protein degraders for relapsed myeloma, from biology and trial data to sequencing, neutropenia management, and residual disease testing. Session Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS Single-cell and spatial maps of bone marrow in acute myeloid leukemia and myelodysplastic neoplasms, showing how immune cell niches help tumors evade immunity. Session Back to the Future: Using Old and New Tools to Move the Field of Plasma Cell Research Forward Old and new tools, from biochemistry and mouse models to spatial gene mapping and AI, revealing weak points and treatment biomarkers in multiple myeloma. Talk Show Me Your Face and I Will Understand Your Purpose: How Protein Structure Informs Function Structural biology uncovered a second route for destroying the transcription factors multiple myeloma depends on, making that pathway a possible drug target. Talk From Frontier to Field: Manufacturing Innovations That Could Lower Barriers to CAR-T Access in LMICs Manufacturing advances from wealthy countries that could make CAR-T therapy cheaper and easier to deliver in low- and middle-income countries. Talk Targeting Acute and Chronic GVHD with Effective New Therapies Recently approved treatments for steroid-resistant acute and chronic graft-versus-host disease, including ruxolitinib, belumosudil, axatilimab and stromal cells. Talk Dealing with Workforce Challenges in Classical Hematology What drives the shortage of specialists in non-cancer blood disorders, and early results from efforts to close the gap. |
Instantly find 20 buyers in lymphoma & CLL
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASH 2026 by
Organization type
Topic
- Leukemias, MDS & MPN 110
- Lymphoma & CLL 81
- Myeloma & Amyloidosis 74
- Bispecifics, ADCs & Targeted Drugs 92
- Transplant, Cell & Gene Therapy 86
- Sickle Cell, Anemia & Red Cell Disorders 76
- Bleeding, Clotting & Platelets 53
- Stem Cells & Blood Biology 52
- AI, Genomics & Data 42
- Clinical Practice & Access to Care 87
Exhibit hall
Everyone
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction